Significant Correlation between Salivary and Serum Ca 15-3 in Healthy Women and Breast Cancer Patients

  • Laidi, Fatna (Oral Biomechanics and Biotechnology Research Unit, Faculty of Dental Medicine, Mohammed 5th Souissi University) ;
  • Bouziane, Amal (Department of Periodontology Faculty of Dental Medicine, Biostatistical, Clinical and Epidemiological Research Laboratory, Faculty of Medicine and Pharmacy, Mohammed 5th Souissi University) ;
  • Lakhdar, Amina (Department of Obstetrics and Gynecology, Ibn Sina University Hospital Rabat) ;
  • Khabouze, Samira (Department of Obstetrics and Gynecology, Ibn Sina University Hospital Rabat) ;
  • Amrani, Mariam (Pathology Department, National Institute of Oncology) ;
  • Rhrab, Brahim (Department of Obstetrics and Gynecology, Ibn Sina University Hospital Rabat) ;
  • Zaoui, Fatima (Oral Biomechanics and Biotechnology Research Unit, Faculty of Dental Medicine, Mohammed 5th Souissi University)
  • Published : 2014.06.15


The tumor marker CA 15-3 is one of the most import reliable for metastatic breast cancer monitoring. While it is generally assessed in serum of patients, blood sampling is an invasive method compared to saliva sampling which is simple and could be an alternative to blood according to many studies. The aim of this investigation was to assess the relationship between serum and salivary concentrations of the protein CA 15-3 in patients with breast cancer and healthy asymptomatic volunteers. A case-control study was conducted with 60 women: 29 breast cancer patients from the Maternity Hospital Souissi Rabat (Morocco) and 31 healthy asymptomatic women. The CA 15-3 concentrations in saliva and serum samples were assessed using an enzyme immune assay (EIA kits) and comparison between cases and controls was made by the Mann-Whitney test. The correlation between serum and saliva CA 15-3 concentration was tested using Pearson correlation. The comparison result of CA15-3 concentration in saliva and serum level in cases and controls was not statistically significant (p>0.05). However, the correlation between salivary and serum CA 15-3 concentration was positive and statistically significant (r=0.27, p=0.03). In conclusion, the positive correlation between salivary and serum expression found in our study suggests that saliva could be an alternative to blood sampling to help breast cancer monitoring.


  1. Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A (2009). Correlation of serum and salivary CA15-3 levels in patients with breast cancer. Medicina Oral S, 10, 521-4.
  2. Atoum M, Nimer N, Abdeldayem S, et al (2012). Relationships among serum CA15-3 tumor marker, tnm staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions. Asian Pac J Cancer Prev, 13, 857-60.
  3. Begum M, Karim S, Malik A, et al (2012). CA 15-3 (mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Asian Pac J Cancer Prev, 13, 5257-61.
  4. Bigler LR, Streckfus CF, Copeland L, et al (2002). The potential use of saliva to detect recurrence of disease in women with breast carcinoma. J Oral Pathol Med, 31, 421-31.
  5. Clinton SR, Beason KL, Bryant S, et al (2003). A comparative study of four serological tumor markers for the detection of breast cancer. Biomed Sci Instrum, 39, 408-14.
  6. Colomer R, Ruibal A, Salvador L (1989). Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer, 64, 1674-81.<1674::AID-CNCR2820640820>3.0.CO;2-V
  7. Dilhuydy M-H (2009). Imagerie au service du depistage : l'exemple du depistage organise du cancer du sein. Bull Cancer, 96, 1071-86.
  8. Frenette PS, Thirlwell MP, Trudeau M, et al (1994) The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. Tumour Biol, 15, 247-54.
  9. Hofman L F (2001). Human Saliva as a Diagnostic Specimen. J Nutr, 131, 1621-5.
  10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  11. Lac G (1998). Interet et champs d'application des dosages salivaires. Science & Sports, 13, 55-63.
  12. Mandel ID (1993). Salivary diagnosis: promises, promises. Ann N Y Acad Sci, 694, 1-10.
  13. Maric P, Ozretic P, Levanat S, et al (2011). Tumor Markers in Breast Cancer-Evaluation of their Clinical Usefulness. Coll Antropol, 35, 241-7.
  14. Mcintyre R, Bigler L, Dellinger T, et al (1999). Oral contraceptive usage and the expression of CA 15-3 and c-erbB-2 in the saliva of healthy women. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 88, 687-90.
  15. Moazzezy N, Farahany T-Z, Oloomi M, et al (2014). Relationship between preoperative serum CA15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev, 15, 1685-8.
  16. Navazesh M, Christensen CM (1982). A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res, 61, 1158-62.
  17. Navazesh M (1993). Methods for collecting saliva. Ann N Y Acad Sci, 694, 72-7.
  18. Nicolini A, Carpi A, Ferrari P, et al (2008). Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study. Cancer Lett, 263, 122-9.
  19. Porika M, Malotu N, Veldandi U-K, et al (2010). Evaluation of tumor markers in Southern Indian breast cancer patients. Asian Pac J Cancer Prev, 11, 157-9.
  20. Ray A (2012). Adipokine leptin in obesity-related pathology of breast cancer. J Biosci, 37, 289-94.
  21. Streckfus C, Bigler L (2005). The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of breast cancer in women: the results of a five-year translational research study. Adv Dent Res, 18, 17-24.
  22. Streckfus C, Bigler L, Dellinger T, et al (1999). CA 15-3 and c-erbB-2 presence in the saliva of women. Clin Oral Investig, 3, 138-43.
  23. Tarhan M-O, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum ca15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev, 14, 1725-9.
  24. Tjemslanda L, Soreide JA (2004). Operable breast cancer patients with diagnostic delay oncological and emotional characteristics. Eur J Surg Oncol, 30, 721-7.
  25. Toth B, Nieuwland R, Liebhardt S, et al (2008). Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res, 28, 1107-12.
  26. Xiaoqiang Tang (2013). Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett, 332, 3-10.
  27. Zhang S-J, Hu Y, Qian H-L, et al (2013). Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev, 14, 3937-40.

Cited by

  1. A Computational Method for Prediction of Saliva-Secretory Proteins and Its Application to Identification of Head and Neck Cancer Biomarkers for Salivary Diagnosis vol.14, pp.2, 2015,
  2. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening vol.17, pp.1, 2016,
  3. Salivary biomarkers in cancer detection vol.34, pp.1, 2017,
  4. Cancer Salivary Biomarkers for Tumours Distant to the Oral Cavity vol.17, pp.9, 2016,